Skip to main content
. 2013 Sep 14;19(34):5622–5632. doi: 10.3748/wjg.v19.i34.5622

Table 1.

Baseline characteristics of the study population n (%)

Variable All treated patients (n = 38) Type of TACE
P value
DEB-TACE (n = 22) c-TACE (n = 16)
Age at LT (yr) 56.5 ± 6.5 57.2 ± 6.5 55.6 ± 6.5 0.4545
Male gender 34 (89.5) 19 (86.4) 15 (93.7) 0.6245
MELD score 10 (6-27) 9 (6-27) 10 (7-16) 0.4688
Etiology of cirrhosis 0.1834
HCV-related 22 (57.9) 10 (45.5) 12 (75.0)
HBV-related 11 (28.9) 8 (36.3) 3 (18.7)
Non-viral 5 (13.2) 4 (18.2) 1 (6.3)
Waiting list time (mo) 3.1 (0.1-26.7) 2.9 (0.1-24.3) 3.3 (0.6-26.7) 0.5844
Interval between last TACE and LT (mo) 3.6 (0.1-15.9) 2.3 (0.2-13.8) 5.5 (0.9-15.9) 0.0625
Repeated TACE 20 (52.6) 12 (54.5) 8 (50.0) 0.7817
Adherence to MC at imaging before TACE 0.3243
Within MC 21 (55.3) 14 (63.6) 7 (43.7)
Beyond MC 17 (44.7) 8 (36.4) 9 (56.3)
BCLC stage before TACE 0.3243
A 21 (55.3) 14 (63.6) 7 (43.7)
B 17 (44.7) 8 (36.4) 9 (56.3)
Number of nodules before TACE 2 (1-5) 2 (1-5) 2 (1-5) 0.8708
Nodule number class before TACE 0.2222
1 nodule 16 (42.1) 8 (36.4) 8 (50.0)
1 < nodules < 4 13 (34.2) 10 (45.4) 3 (18.8)
Nodules ≥ 4 9 (23.7) 4 (18.2) 5 (31.2)
1Serum α-fetoprotein > 70 ng/mL 8/33 (24.2) 3/18 (16.7) 5/15 (33.3) 0.4811
Post-LT follow-up (mo) 39.9 ± 22.5 34.9 ± 19.0 46.8 ± 25.6 0.1065

Continuous variables are reported as the mean and standard deviation or median and range and compared using Student’s t test or the Mann-Whitney U test as appropriate. Categorical variables are reported as numbers and percentages.

1

Value of serum α-fetoprotein was not available for 5 patients. TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; MC: Milan Criteria; LT: Liver transplantation; HCV: Hepatitis C virus; HBV: Hepatitis B virus; MELD: Model for End Stage Liver Disease; c-TACE: Conventional TACE; BCLC: Barcelona Clinic Liver Cancer.